Balance, Autonomic Response, and Sensory Modulation to Dosage of Mechanical Vagal Stimulation in Healthy Adults
NCT Number: NCT06541808
Acronym: BARVANS
Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL
Phases: NA
Conditions: Vagus Nerve Autonomic Disorder|Heart Rate|Pain|Equilibrium; Disorder, Labyrinth|Microbial Colonization
Interventions: OTHER: mechanical Vagus Nerve Stimulation (Low Intensity)|OTHER: mechanical Vagus Nerve Stimulation (Intermediate Intensity)|OTHER: mechanical Vagus Nerve Stimulation (High Intensity)
Sponsor: University of Vienna
Collaborators: Dr David Gomez Varela PhD|Prof. Dr. Manuela Schmidt PhD
Sex: ALL
Age: ADULT
Enrollment: 96
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2024-09-02
Completion Date: 2025-09-30

Summary:
The vagus nerve (VN) plays a crucial role in regulating vital functions (heart rate, blood pressure, digestion, and immune response) and maintaining communication between internal organs and the brain. Recent studies have highlighted the therapeutic potential of VN stimulation (VNS) in treating various conditions such as drug-resistant epilepsy, postural control deficit, COVID-19 infection, chronic pain, and intestinal disorders. In addition, there is growing evidence that the molecules released by the VN neurons affect the function of the gut microbiota and that the molecules released by the bacteria in our gut affect the activity of the VN neurons. In particular, Dr. Giacomo Carta (the leader of this study) has shown how painless neck movements, i.e. mechanical VNS (mVNS), can be applied without adverse effects, representing a potential alternative to invasive methods commonly used today. To further investigate the impact of this novel mVNS, this study aims to evaluate the changes induced by three mVNS protocols on physiological parameters such as resting heart rate, and Heart Rate Variability (HRV) at rest, balance in standing, the perceived intensity of mechanical stimuli using the established clinical method of QST (quantitative sensory testing), fecal transit speed, and the molecular composition of stool (for this, stool samples are analyzed). In particular, stool analysis is very relevant for understanding normal digestion. The present research aims to define the optimal intensity of mVNS and to investigate the therapeutic potential of VNS in the treatment of autonomic dysfunction (such as too low or too high heart rate, too low or too fast digestion, throbbing headaches), as well as falls prevention and pain.

Primary Outcome Measures: Heart Rate at rest, Heart rate is recorded continuously from 2 minutes before to 2 minutes after the stimulation using a fingertip infrared pulse oximeter. Heart rate will be measured in beats per minute., The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol|Heart Rate Variability at rest, Polar H10 (1000 Hz) Chest Strap (rubber band placed comfortably around the chest above the xiphoid process level) for data acquisition will be worn by the participant for the duration of the assessment and the stimulation protocol. ECG waves will be acquired via Bluetooth to Elite HRV (Version 5.5.9, Asheville, NC, USA) on an Android device. HRV results from Elite HRV displayed on the app will be recorded for analysis with an Open HRV reading 2 minutes before the stimulation and 2 minutes immediately after. At the end of the data acquisition session, the chest strap will be removed. Distance between R peaks in the ECG, defined as RR Interval (Interbeat intervals \[IBIs\]) will be used as a reference to define HRV., The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol|Mechanical Pain Intensity, These tests will be adopted to assess peripheral and central sensitization phenomena. Tests will be administered once for each site, using Neuropen with a Neurotip (disposable needle with a defined pressure of 40 g) and by applying 75 g pressure monofilament for 2 seconds on the skin site.

If the stimulus is perceived as a pinprick by the participant, it will be requested to rate the pain intensity (NRS, "0 = no pain" to "10 = worst imaginable pain")., The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol
Secondary Outcome Measures: Wind-up ratio, The temporal summation will be tested by comparing the pain rating of a single pinprick stimulus and a train of 10 pinprick stimuli of the same force repeated at a rate of 1/second using 75 g pressure monofilament on the same squared centimetre of skin area. The stimuli will be administered on the skin of the forehead (2 cm above the eyebrow and pupil center), on the neck above the middle of the sternocleidomastoideus muscle belly, and the abdomen (middle of the lines connecting the umbilicus to the anterior superior spina iliaca).

If the stimulus is perceived as a pinprick by the participant, it will be requested to rate the pain intensity (NRS, "0 = no pain" to "10 = worst imaginable pain").

The test will be repeated 5 times, and the mean pain rating of trains divided by a single stimulus was defined as the WUR., The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol|One-leg support test, Balance will be tested by standing on the dominant leg with eyes closed, freeing the hands from a rail positioned in front of the participant, and maintaining the balance after the test has begun (hearing an acoustic signal). Further attempts can be performed until three successful attempts are completed without touching the ground with the non-dominant leg or opening the eyes for at least 20 seconds. During the test, participants are supported by an experimenter who stands next to them and is ready to provide assistance., The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol|Mechanical pressure intensity, Participants' mechanical pressure intensity will be assessed by the intensity rate of the stimuli using a numerical rating scale (0-10 no pain - the worst ever imagined) on the skin of the forehead (2 cm above the eyebrow and pupil center), on the neck above the middle of the sternocleidomastoideus muscle belly, and the abdomen (middle of the lines connecting the umbilicus to the anterior superior spina iliaca) using a standardized pressure of 1 and 10 gr monofilament., The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol|The Gastrointestinal Symptom Rating Scale, The scale consists of 13 items that assess the intensity of symptoms (each item is rated on a 7-point Likert scale; 1=No discomfort at all - 7= Very severe discomfort) related to gastrointestinal problems (i.e. possible symptoms such as difficulty or pain in digesting some foods; GSRS). The higher the score, the more gastrointestinal symptoms are present. A minimum score of 13 indicates no gastrointestinal symptoms. A maximum score of 101 indicates a severe presence of gastrointestinal symptoms., The outcome will be measured before the stimulation protocol, immediately after the stimulation protocol, and one week after the stimulation|The Bristol Stool Form Scale, This validated scale allows determining whether digestion is normal, too slow or too fast based on the shape of the stool (BSFS). After a visual inspection of the stool, it is requested to give a rating using the shapes provided.

The BSFS takes 30 seconds to complete and is required to complete the scale after the first bowel movement of the day. 7 type of stool are depicted and described. A sausage-shaped poop with cracks on the surface (Type 3) is considered normal on the Bristol Stool Scale. Type1-2 means too slow gastric transit while Type 4-7 too fast gastric transit.

A sheet on which the daily scores will be reported by the participant will be provided after the agreement to participate and the signing of the informed consent., The outcome will be measured for 1 week before and for 2 weeks after the administration of e week after the stimulation|Gut microbiota composition and function, Two stool sample kits will be provided to the participants so that they can collect a sample from the first bowel movement of the day and immediately after the stimulation protocol.

Participants will be asked to bring the sample as soon as possible to the laboratory where they will be conserved and analysed. Metaproteomic analysis of each sample will be performed to estimate the gut microbiota composition by Shannon index to estimate the α-diversity (number of taxa/sample) and by Jaccard distance (defined as the ratio of taxa shared between samples/total number of taxa) to estimate the ß-diversity index. Gut microbiota function will be estimated by adopting the identified pathways of bacteria from the Kyoto Encyclopedia for Genes and Genomes (KEGG). The total protein intensity belonging to each pathway in each sample will be adopted for the analyses, The outcome will be measured before the stimulation protocol and immediately after the stimulation protocol